The Vancouver biotech firm is working on a new kind of regenerative medicine by bioprinting living human tissue. The federal money will go toward Aspect’s $280-million project to advance the company’s biomanufacturing capabilities, improve its AI-powered platform and help it commercialize its work. (The Logic)
Talking point: Industry Minister Mélanie Joly said the contribution will help establish Canada’s first bioprinting facility for tissue therapeutics. The department didn’t immediately say whether the contribution is a loan or a grant. The government’s goal is to help make Vancouver a global life-science hub, she said. Ottawa’s contribution comes from the recently rebranded Strategic Response Fund (formerly the Strategic Innovation Fund), and the B.C. government has agreed to contribute an additional $23.8 million. Both governments also contributed a combined $72.75 million to the company in 2024. CEO Tamer Mohamed said the company has raised more than half a billion dollars and he hopes to turn it into a $100-billion company anchored in Canada.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.